Shkodra Morena, Caraceni Augusto
Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy.
Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway.
Cancers (Basel). 2022 Apr 14;14(8):1992. doi: 10.3390/cancers14081992.
Neuropathic pain can be defined as pain related to abnormal somatosensory processing in either the peripheral or central nervous system. In this review article, with neuropathic cancer pain (NCP), we refer to pain due to nervous tissue lesions caused by the tumor or its metastases. Nervous tissue damage is the cause of cancer pain in approximately 40% of those experiencing cancer pain. Recognizing a neuropathic pathophysiology in these cases may be difficult and requires specific criteria that are not homogenously applied in clinical practice. The management of this type of pain can be challenging, requiring the use of specific non-opioid adjuvant drugs. The majority of the criteria for NCP diagnosis and management have been based mainly on results from the noncancer population, risking the failure of addressing the specific needs of this population of patients. In this review, we summarize current management options available for NCP and provide some insights on new promising treatments.
神经病理性疼痛可定义为与外周或中枢神经系统中异常的躯体感觉处理相关的疼痛。在这篇综述文章中,对于神经病理性癌痛(NCP),我们指的是由肿瘤或其转移灶引起的神经组织损伤所致的疼痛。在大约40%经历癌痛的患者中,神经组织损伤是癌痛的原因。在这些病例中识别神经病理性病理生理学可能很困难,并且需要在临床实践中未得到统一应用的特定标准。这类疼痛的管理可能具有挑战性,需要使用特定的非阿片类辅助药物。NCP诊断和管理的大多数标准主要基于非癌症人群的结果,有可能无法满足这类患者群体的特定需求。在本综述中,我们总结了目前可用于NCP的管理选择,并对新的有前景的治疗方法提供一些见解。